Caris Life Sciences, Inc.
CAI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $9 | $7 | $7 | $7 |
| - Cash | $1 | $1 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $8 | $7 | $8 | $7 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 19.5% | 50% | 20.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 68% | 62.7% | 47.2% | 37.5% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 19.7% | -25.5% | -68.4% | -40.9% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 11.2% | -39.6% | -84.8% | -66.2% |
| EPS Diluted | 0.082 | -1.87 | -0.4 | -0.35 |
| % Growth | 104.4% | -367.5% | -14.3% | – |
| Operating Cash Flow | $0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | -$0 |